Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

November 20, 2018

Study Completion Date

May 29, 2020

Conditions
HIV-1 Infection
Interventions
DRUG

B/F/TAF

50/200/25 mg FDC tablet administered orally once daily without regard to food.

Trial Locations (25)

1000

CHU Saint-Pierre, Brussels

6203

CHU de Nice, Nice

8916

Hospital Universitari Germans Trias i Pujol, Badalona

9000

UZ Gent, Ghent

13006

Hopital Europeen Marseille, Marseille

20157

ASST - Fatebenefratelli Sacco, Milan

24127

ASST Papa Giovanni XXIII, Bergamo

28007

Hospital General Universitario Gregorio Maranon, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

29603

Hospital Costa Del Sol, Marbella

33064

Interne et Maladies infectieuses, Pessac

33075

Hopital Saint-Andre, Bordeaux

44093

C.H.U. de Nantes - Hotel Dieu, Nantes

59208

CH de Tourcoing, Tourcoing

65124

P.O. Spirito Santo - U.O. Malattie Infettive e Tropicali, Pescara

75015

Hopital Necker - Enfants Malades, Paris

75475

Hopital Saint Louis, Paris

75571

Hopital Saint Antoine, Paris

00149

IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma

08026

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

NE1 4LP

Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT03405935 - Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years | Biotech Hunter | Biotech Hunter